首页|药物GLP体系下的多场所研究策略

药物GLP体系下的多场所研究策略

扫码查看
目的:探讨药物非临床研究质量管理规范(Good Laboratory Practice,GLP)体系下多场所研究策略的制定。方法:分析多场所研究开展前对分场所的考察、多场所研究中各级人员的职责与沟通协作方式以及几种多场所研究开展的策略等内容。结果:多场所研究是一项具有一个研究计划和一份最终报告的研究,必须符合GLP,因此应选择完全符合GLP标准的实验室作为分研究场所,在多场所研究开展前应仔细规划,界定好相关人员的沟通方式和职责,专题负责人作为研究的唯一控制点,必须在确保合规方面发挥核心作用。结论:在药物GLP体系下制定符合国内外GLP法规要求的多场所研究策略,必须掌握多场所研究是一项单一研究的原则,选择GLP实验室为分研究场所,仔细规划,各级人员严格履行各自的职责并建立顺畅的沟通方式,专题负责人应充分发挥推动者的角色。
Multi-site Study Strategy Under Drug GLP System
Objective:To explore the formulation of multi-site study strategy under drug GLP system.Methods:The investigation of sub-sites before the multi-site study,the responsibilities and ways of communication and cooperation modes of staff at all levels in the multi-site study,and several strategies for conducting multi-site study were analyzed.Results:A multi-site study was a study with a research plan and a final report,which must comply with GLP standards.Therefore,a laboratory that fully complied with GLP standards should be selected as a sub-site.Before the multi-site study,careful planning should be carried out to define the communication methods and responsibilities of relevant personnels,and as the only control point of the study,SD must play a central role in ensuring compliance.Conclusion:To formulate a multi-site study strategy that meets the requirements of GLP regulations at home and abroad under the drug GLP system,it is necessary to grasp the principle that multi-site study is a single study,select the GLP laboratory as a sub-research site,carefully plan,and staff at all levels strictly perform their responsibilities and establish smooth communication methods,so that SD can fully play the role of facilitator.

multi-site studyGLPresponsibilitycommunicatedrug regulation

潘秋兰、吴紫君、柳璐、郭健敏、雷夏凌、杨威

展开 >

广州湾区生物医药研究院,广东莱恩医药研究院有限公司,广东省药物非临床评价研究企业重点实验室,国家中药现代化工程技术研究中心中药非临床评价分中心,广东省创新药物评价与研究工程技术研究中心,广州 510990

多场所研究 GLP 职责 沟通 药品监管

国家重点研发计划广东省科技领军人才项目

2022YFC0870700210183503006

2024

中国药事
中国食品药品检定研究院(中国药品生物制品检定所)

中国药事

CSTPCD
影响因子:0.844
ISSN:1002-7777
年,卷(期):2024.38(6)